Judith Dunn

Judy is an EIR and has held leadership positions in both biotech and large pharma including President of Research and Development at Fulcrum Therapeutics and Vice President of Clinical Development at Roche in Basel, Switzerland. Judy has a deep interest in neuroscience and has held positions of increasing responsibility in both the research and commercial neuroscience divisions of Pfizer and in clinical psychiatry at Sepracor (Sunovion). As a prior EIR at Atlas, Judy participated in the formation of Vigil Neuroscience. She serves on the Board of Directors of Eliem Therapeutics and Evolution Research Group. Judy attended Wesleyan University and the University of Rochester, obtaining undergraduate and graduate degrees in Neurobiology. She completed research fellowships in Neuropharmacology at the Center for Brain Research at Strong Memorial Hospital and in Clinical Research at Pfizer.